TC BioPharm (NASDAQTCBP) announced that CEO Bryan Kobel will participate in the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum on Feb. 27 at 1:10 p.m. CET in Zurich. The forum, set for Feb. 26-27 at the Hilton Zurich Airport Hotel, will feature discussions on AI, diagnostics, and health technology, with over 12 hours of keynotes and panels on industry advancements.

TC BioPharm (NASDAQTCBP) announced the completion of patient dosing in Cohort A of its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for relapsed or refractory acute myeloid leukemia (AML). Early data indicate a favorable safety profile, with no drug-related adverse events, and show multiple patients achieving stable disease following treatment. Recruitment into Cohort B remains ongoing as the company refines its clinical strategy for TCB008, including its potential as a bridge to transplant or in combination therapies.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

TC BioPharm (NASDAQTCBP) has completed full dosing for the first Cohort B patient in its Phase 2B ACHIEVE clinical trial evaluating TCB008 for acute myeloid leukemia (AML) in the UK. The study, assessing the therapy’s safety and efficacy, has shown no drug-related adverse events. Recruitment for Cohort B, which includes patients in remission with minimal residual disease, began ahead of schedule in late 2024, with enrollment for a second patient underway. CEO Bryan Kobel highlighted the therapy’s potential for AML patients facing limited treatment options, with full cohort enrollment expected in the first half of 2025 and data readout later this year.

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company, announced a change in the ratio of its American Depositary Shares (“ADSs”) to ordinary shares from 1 ADS representing 200 ordinary shares to 1 ADS representing 4,000 ordinary shares, effective Feb. 10, 2025. The adjustment will function as a 1-for-20 reverse ADS split but will not affect the total number of underlying ordinary shares. The Bank of New York Mellon, the company’s depositary bank, will manage the exchange, with fractional entitlements aggregated and sold, and proceeds distributed to holders. TC BioPharm expects the ADS trading price to rise proportionally but does not guarantee specific price outcomes.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

TC BioPharm (NASDAQTCBP), a clinical-stage biotech company, announced plans to initiate Proof of Concept preclinical studies for its lead therapy, TCB008, targeting H5N1 “bird flu.” TCB008 is an allogeneic gamma delta T cell therapy designed to leverage the immune system against infections like H5N1, which recently caused the first reported U.S. fatality in Louisiana. TC BioPharm aims to collaborate with leading infectious disease centers or universities to expedite studies and prepare for a Phase I trial. CEO Bryan Kobel emphasized TCB008’s potential in addressing infectious diseases, underscoring the company’s commitment to combating emerging health threats.

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company advancing allogeneic gamma-delta T cell therapies for cancer and other diseases, announced that CEO Bryan Kobel will present a corporate overview at the Sequire Investor Summit 2025. The conference will take place Jan. 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

TC BioPharm (NASDAQTCBP), a clinical-stage biotech company focused on gamma-delta T cell therapies for cancer, announced that its American Depository Shares remain actively traded on the Nasdaq Global Select Market under the ticker symbol “TCBP.” The company clarified that there has been no trading halt and that shares are expected to trade without interruption. This announcement does not constitute any offer or solicitation regarding securities transactions.

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company focused on gamma-delta T cell therapies, announced shareholder approval of a 25% special stock dividend. Shareholders of record as of Jan. 2, 2025, will receive 0.25 American Depositary Shares (“ADSs”) for every 1 ADS held, with distribution expected around January 6, 2025. CEO Bryan Kobel emphasized the dividend as a reflection of confidence in the company’s financial outlook and a strategic move to enhance shareholder value. Nasdaq trading of TCBP ADSs will pause temporarily from January 2 to January 8 to facilitate the dividend process.

TC BioPharm (NASDAQTCBP) announced encouraging progress in its ACHIEVE Phase 2b trial in the UK, with three patients completing the full-dose regimen of TCB008 with no drug-related adverse events. The trial, evaluating TCB008 for AML and MDS/AML, has enrolled 10 patients so far, with nine receiving their second dose, four their third dose, and three their final dose. Preliminary safety data indicates the 5mL dose is well-tolerated, supporting the study’s safety objectives. Recruitment has advanced swiftly, with nine of 14 planned patients for Cohort A (relapsed/refractory disease) and one for Cohort B (minimal residual disease) enrolled. Company executives noted the trial’s rapid progress and the potential for expedited review in Cohort B, as the team focuses on completing recruitment and data analysis in 2025.

TC BioPharm (NASDAQTCBP) has announced a special dividend of 0.25 American Depositary Shares (“ADSs”) for every 1 ADS held, subject to shareholder approval. The decision will be discussed during a General Meeting on December 30, 2024, in Scotland, with the dividend payable to shareholders holding stock at market close on January 2, 2025. CEO Bryan Kobel highlighted the dividend as a reward for shareholder loyalty amid challenging market conditions and expressed confidence in delivering further operational successes in 2025. Details are available on the company’s website and the SEC’s platform.

TC BioPharm to issue a special dividend of 0.25 ADS per share, pending shareholder approval at the December 30 meeting. Record date: January 2, 2025.

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, has partnered with CareDx, Inc. NASDAQ: CDNANASDAQCDNA)

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has announced an update on the progression of the ACHIEVE UK Trial. “Medicinal products cannot be effective if they are not safe, and it’s clear from these initial data that TCB008 is safe for our patients,” said Executive VP of Clinical Operations, Alison Bracchi. “Our priority now, for Cohort A, is to find the optimal biologically effective dose for patients that have exhausted all other treatments to drive a long term response. We look forward to completing the recruitment of Cohort B patients and are planning to evaluate these data in the first half of 2025.”

Standard Lithium (NYSE American: SLI) reported robust fiscal Q1 2025 progress, highlighted by a $225 million conditional grant from the U.S. Department of Energy, marking one of the largest grants awarded to a U.S. critical minerals project. This funding supports the construction of Phase 1 for the South West Arkansas (“SWA”) lithium project, anticipated to produce 22,500 tonnes of lithium carbonate annually by 2028. David Park, newly appointed CEO, is steering the company’s focus toward production, advancing off-take agreements, and partnering with Equinor. Additionally, Standard Lithium has adopted Koch Technology Solutions’ advanced lithium extraction technology for use in the SWA project’s commercial facility.

TC BioPharm (NASDAQTCBP), a clinical-stage biotech firm developing gamma-delta T cell therapies, reported key 2024 achievements, highlighting progress in the ACHIEVE UK trial, with eight patients dosed and new trial sites established, including Guy’s and St. Thomas Hospital. The company also launched a compassionate use program for TCB008 and signed two non-binding LOIs for potential acquisitions in CAR-T and NK therapy technologies. TC BioPharm collaborated with the University of Surrey on preclinical Mpox studies and partnered with Carnegie Mellon University on AI-driven donor screening for cell therapies. Cost efficiencies have increased treatment capacity, while a Q3 capital raise of $8 million bolstered its balance sheet, positioning TC BioPharm to continue advancing its strategic initiatives into 2025.